FDA Accepts Pembrolizumab Biosimilar BLA for Review

Formycon and Zydus say FDA accepted for review the BLA for FYB206, a pembrolizumab biosimilar, marking the first publicly announced acceptance for a KEYTRUDA biosimilar in the US.